GLAXO MTF Data: Margin Funding in GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited has ₹19.53 crore financed under MTF, 0.04% of its shares. The book is up 8.1% in a month and down 40.8% in a year. Shares financed fell 36% over the year: margin holders have been exiting. At the last close the financed shares were worth 10.6% less than the amount financed.
GLAXO MTF book and price
Daily for the last two years, weekly before that. The book is the exchange-reported amount financed.
Holders' cost vs the market
Amount financed ÷ shares financed approximates the average price margin holders paid. When the close is below that line, margin holders are, on average, sitting on a loss.
Shares financed
Share counts move only when margin holders buy or sell (and on splits and bonuses), not with the price.
Net new margin buying, by month
Each day's change in shares financed valued at that day's close, summed by month: buying and selling on margin without the effect of price. Split and bonus credits are removed.
Leverage and days to cover
Share of the company's shares on margin (month end) and how many days of average NSE volume they equal.
Records & stats
| Latest book | ₹19.53 Cr |
| Flow: 1 / 5 / 20 sessions | +₹2.4 L · +₹14.5 L · +₹1.34 Cr |
| Change: 1 week / 1 month / 3 months / 1 year | +0.8% · +8.1% · -25.0% · -40.8% |
| All-time high | ₹64.54 Cr 25 Nov 2024 |
| Low since first funded | ₹1.9 L 18 Oct 2017 |
| Biggest one-day build | +₹42.41 Cr 22 Nov 2024 |
| Biggest one-day unwind | −₹17.68 Cr 26 Nov 2024 |
| Below its peak | 69.7% |
| Average book while funded | ₹10.88 Cr |
| Most shares financed | 2.71 lakh 25 Nov 2024 |
| Funded since | 22 Jun 2017 (2,235 sessions with a book) |
Month by month
| Month | Book | Net buying | % of shares | Days to cover |
|---|---|---|---|---|
| 2026-10 | ₹19.53 Cr | −₹25.6 L | 0.04% | 1.5 |
| 2026-09 | ₹19.93 Cr | +₹2.57 Cr | 0.04% | 0.9 |
| 2026-08 | ₹16.95 Cr | −₹8.52 Cr | 0.04% | 0.3 |
| 2026-07 | ₹24.13 Cr | −₹2.11 Cr | 0.05% | 1.2 |
| 2026-06 | ₹25.96 Cr | −₹19.04 Cr | 0.06% | 0.7 |
| 2026-05 | ₹45.98 Cr | +₹18.68 Cr | 0.11% | 1.6 |
| 2026-04 | ₹26.13 Cr | +₹2.17 Cr | 0.06% | 1.6 |
| 2026-03 | ₹24.18 Cr | −₹2.48 Cr | 0.05% | 1.6 |
| 2026-02 | ₹27.92 Cr | −₹4.03 Cr | 0.06% | 1.3 |
| 2026-01 | ₹31.84 Cr | −₹2.61 Cr | 0.07% | 1.6 |
| 2025-12 | ₹35.09 Cr | +₹1.15 Cr | 0.07% | 1.2 |
| 2025-11 | ₹34.37 Cr | +₹85.7 L | 0.07% | 1.2 |
Other Pharmaceuticals & Biotechnology stocks on margin
Split and bonus adjustments
Dates on which the exchange re-based this stock's previous close (splits, bonuses and similar actions). Prices on the charts are shown as traded; share counts jump on these dates when brokers credit the new shares.
- 11 Sep 2018: price re-based by a factor of 0.5000 (about 2.00 new shares for each old one)
Questions
How much margin trading funding does GLAXO have?
On 22 Oct 2026, ₹19.53 Cr of GlaxoSmithKline Pharmaceuticals Limited shares were held under the margin trading facility, 69,007 shares on NSE.
What share of GLAXO is bought on margin?
About 0.04% of all its shares and 0.16% of its free float.
Are margin holders of GLAXO in profit?
At the last close the financed shares were worth 10.6% less than the amount financed. The amount financed reflects purchase values, so this is an estimate of margin holders' average unrealised gain or loss.
Where does this data come from?
Exchange data: the daily margin trading disclosures, with prices and share counts from the exchange. See the methodology.
Figures for the 22 Oct 2026 session · last updated 2026-10-26 20:38 IST · Source: Exchange data · 10/10 data checks passed.
How to read this page. Everything here describes what the exchanges have already disclosed about margin-funded (MTF) positions. It is not a forecast, a recommendation, or a signal to buy or sell. Words such as "crowded", "fragile" or "underwater" name a pattern in the numbers, nothing more. Margin funding carries the risk of losses larger than the money you put in.
Flash Finance is not a SEBI-registered investment adviser and is not affiliated with NSE, BSE or SEBI. Exchange data may be revised by the exchange. Verify anything you intend to act on against the exchange's own records.
